Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Record History

1. Minor Sep 17, 2026 Study Status, Study Design, Referencesv7
2. Minor Mar 26, 2015 Collaborator revisedv6 See this version in full on ClinicalTrials.gov ↗
3. Minor May 9, 2008 Trial status: Recruiting to Completed Enrollment target: 44 to 43 · Primary completion date: Dec 2006 · Study description expanded, about 16 words · 1 morev5 Show 4 more changesShow less

   • Enrollment target: 44 to 43
   • Primary completion date: Dec 2006
   • Study description expanded, about 16 words
   • Site details revised at 2 of 2 sites

   See this version in full on ClinicalTrials.gov ↗

4. Minor Nov 13, 2006 Completion date: Nov 2005 to Dec 2006 Site details revised at 1 of 2 sites · Collaborator revised · Study title revisedv4 Show 3 more changesShow less

   • Site details revised at 1 of 2 sites
   • Collaborator revised
   • Study title revised

   See this version in full on ClinicalTrials.gov ↗

5. Minor Dec 21, 2005 Site details revised at 1 of 2 sitesv3
6. Minor Sep 13, 2005 Study sites: 1 to 2 Collaborators expanded, about 3 wordsv2 Show 1 more changeShow less

   • Collaborators expanded, about 3 words

   See this version in full on ClinicalTrials.gov ↗

7. Minor Sep 2, 2005 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.